Search

Displaying results 1891 - 1900 of 8195 in total
  1. Drug

    PF-04991532

    go.drugbank.com/drugs/DB11765
    Investigational

    PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Glucose Metabolism Disorders.

  2. Drug

    PL-3994

    go.drugbank.com/drugs/DB15355
    Investigational

    PL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).

  3. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. … In July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients.

  4. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    [Flotufolastat] F-18 (<sup>18</sup>F-rhPSMA-7.3) is an <sup>18</sup>F-labeled ligand that targets the prostate-specific membrane antigen (PSMA). … Unlike <sup>68</sup>Ga-labeled PSMA-targeting ligands, <sup>18</sup>F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches.

  5. Drug

    Oseltamivir

    go.drugbank.com/drugs/DB00198
    ApprovedInvestigational

    Notably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness. … [A179962, A179965, A179968] Due to the risk of adverse effects such as nausea, vomiting, psychiatric effects and renal adverse events in adults and vomiting in children, the harms are generally considered

  6. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. … Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 SubstratesSynonyms: 1-Butyl-3-(p-tolylsulfonyl)urea, 1-p-Toluenesulfonyl-3-butylurea
  7. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. It was part of the first generation of commercially available artificial surfactants. It was developed by Burroughs Wel...

    Synonyms: Palmitate de colfosceril, Palmitato de colfoscerilo
  8. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. … It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  10. Drug

    Radium Ra-223

    go.drugbank.com/drugs/DB12813
    Investigational

    Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).